Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.52 |
| ▸ | CNR1 | P21554 | 4/20 | 0.52 |
| ▸ | PRKACA | P17612 | 2/20 | 0.51 |
| ▸ | PRKACG | P22612 | 2/20 | 0.51 |
| ▸ | PRKACB | P22694 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490778 | 0.89 | CNR2 (0.56) | CNR2CNR1PRKACAPRKACGPRKACB | |
| SCHEMBL24199359 | 0.84 | CNR2 (0.53) | CNR2CNR1PRKACAPRKACGPRKACB | |
| SCHEMBL24199375 | 0.82 | CNR2 (0.51) | CNR2GSK3BALDH1A1POLB | |
| SCHEMBL88821 | 0.81 | CNR2 (0.57) | CNR2CNR1PRKACAPRKACGPRKACB | |
| SCHEMBL23497774 | 0.80 | POLB (0.60) | CNR2CNR1PRKACAPRKACGPRKACB | |
| SCHEMBL29744400 | 0.80 | POLB (0.60) | CNR2CNR1PRKACAPRKACGPRKACB | |
| SCHEMBL13131360 | 0.79 | CDC25A (0.54) | CNR2CNR1PRKACAPRKACGPRKACB | |
| SCHEMBL9028491 | 0.79 | LMNA (0.63) | CNR2CNR1NPSR1ALDH1A1 | |
| SCHEMBL4617648 | 0.79 | CNR2 (0.51) | CNR2CNR1PRKACAPRKACGPRKACB | |
| SCHEMBL10729312 | 0.78 | PTGER4 (0.60) | ALDH1A1PTGER4HPGDRXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | CNR2 4520/4885CNR1 3579/4885PRKACA 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.